Larimar Therapeutics (NASDAQ:LRMR) Announces Earnings Results

Larimar Therapeutics (NASDAQ:LRMR – Get Free Report) issued its earnings results on Monday. The company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.06, FiscalAI reports.

Larimar Therapeutics Price Performance

NASDAQ LRMR opened at $2.99 on Wednesday. Larimar Therapeutics has a 1 year low of $1.91 and a 1 year high of $6.42. The stock has a market capitalization of $310.60 million, a PE ratio of -1.83 and a beta of 0.73. The company’s 50 day simple moving average is $2.90 and its two-hundred day simple moving average is $3.75.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on LRMR shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Larimar Therapeutics in a report on Thursday, October 15th. Wall Street Zen cut Larimar Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday. Wedbush dropped their price objective on Larimar Therapeutics from $11.00 to $9.00 and set an “outperform” rating on the stock in a report on Monday. Finally, Leerink Partners initiated coverage on Larimar Therapeutics in a report on Monday, September 14th. They set an “outperform” rating and a $13.00 target price for the company. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Larimar Therapeutics presently has a consensus rating of “Buy” and an average price target of $10.00.

Read Our Latest Research Report on Larimar Therapeutics

Insider Activity

In other news, CEO Carole Ben-Maimon purchased 18,050 shares of Larimar Therapeutics stock in a transaction dated Wednesday, November 11th. The stock was purchased at an average cost of $2.77 per share, for a total transaction of $49,998.50. Following the transaction, the chief executive officer directly owned 386,326 shares of the company’s stock, valued at approximately $1,070,123.02. This trade represents a 4.90% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Michael Celano purchased 18,460 shares of Larimar Therapeutics stock in a transaction dated Wednesday, November 11th. The shares were purchased at an average price of $2.71 per share, with a total value of $50,026.60. Following the completion of the transaction, the chief financial officer directly owned 234,245 shares in the company, valued at approximately $634,803.95. This represents a 8.55% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders bought 140,810 shares of company stock valued at $381,955 in the last quarter. 4.00% of the stock is currently owned by company insiders.

About Larimar Therapeutics

(Get Free Report)

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Bala Cynwyd, Pennsylvania, focused on developing treatments for rare diseases. Its lead drug candidate is nomlabofusp, formerly known as CTI-1601, an engineered fusion protein designed to deliver frataxin to mitochondria. Nomlabofusp is being developed to treat Friedreich’s ataxia, a rare, inherited neurodegenerative disorder associated with insufficient frataxin. Larimar’s approach uses a cell-penetrating peptide to transport frataxin into cells and mitochondria, with the goal of addressing an underlying cause of the disease rather than only treating its symptoms.

Featured Stories

Earnings History for Larimar Therapeutics (NASDAQ:LRMR)

Receive News & Ratings for Larimar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Larimar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.